Power Stick Deodorant Recall: How to return and get refund? See product types, quantities, affected lot numbers, fda report, recall reason, retail stores
The recall was announced by the US Food and Drug Administration (FDA) after the company reported deviations from current Good Manufacturing Practices (cGMP). The affected products were sold at major retailers including Walmart, Dollar Tree and Amazon.
Power Stick Deodorant Recall Types and Quantities
The recall includes three types of Power Stick roll-on antiperspirant deodorants.
Explore courses from Top Institutes in
Select a Course Category
Management
Artificial Intelligence
Public Policy
Degree
Project Management
Data Science
healthcare
Others
Finance
Digital Marketing
Operations Management
Leadership
Healthcare
MBA
CXO
others
PGDM
Design Thinking
Technology
Data Science
Data Analytics
Product Management
MCA
Cybersecurity
Skills you'll gain:
Duration:
9 Months
IIM Calcutta
CERT-IIMC APSPM India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK GMPBE India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIM Kozhikode
CERT-IIMK General Management Programme India
Starts on
undefined
Get Details
Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh (1.8 oz/53 mL): 21,265 cases
Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh (1.8 oz/53 mL): 22,482 cases
Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant (1.8 oz/53 mL): 23,467 cases
Power Stick Deodorant Recall Affected Lot Numbers
Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh:
032026B011
032226B031
051626C241
061526C882
071226D371
071226D381
082526E341
082826E402
Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh:
031726A991
041226B561
062026C901
062026C911
071026D351
071026D361
071326D391
111626G231
Live Events
Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant:
101225D781
032926B281
032826B221
041126B531
062226D011
070626D301
070626D333
111026G051
111326G091
111626G221
Power Stick Deodorant Recall FDA Report and Recall Reason
The recall was listed in an FDA enforcement report. It noted the reason for the recall as 'cGMP deviations.' This means the products were made outside the standards outlined by the FDA's Current Good Manufacturing Practice regulations. The recall was initiated on July 10, 2025.
Also Read:
Who fired Maurene Comey and Why? See ex-FBI Director daughter's high profile cases and what happened on day of departure
Which Stores Sold These Products?
The deodorants were shipped across the United States. They were available for purchase at Walmart, Dollar Tree and on Amazon. The products were manufactured at A.P. Deauville's factory in Pennsylvania, which the company says is FDA-regulated.
Company Background and Additional Products
A.P. Deauville is based in Easton, Pennsylvania. The company manufactures personal care products including shampoos, conditioners, body washes, lotions and facial wipes. It reported the issue voluntarily to the FDA and initiated the recall process.
Also Read:
Tomorrowland 2025: Will festival go as planned? See organizers statement, event schedule, venue, expected visitors and full list of performers
How to Return and Get Refund?
Consumers who have purchased any of the affected Power Stick deodorant products are advised to stop using them immediately. They should contact A.P. Deauville for guidance on returns, refunds, or disposal of the items.
FAQs
What should I do if I purchased a recalled Power Stick deodorant?
Stop using the product immediately and contact A.P. Deauville for return instructions or refund.
Where were the recalled deodorants sold?
They were sold nationwide at Walmart, Dollar Tree and Amazon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
41 minutes ago
- New Indian Express
Karnataka collects 32.68 lakh litres of used oil; orders stricter checks on reuse, fortification
BENGALURU: In response to the collection of more than 32.68 lakh litres of used cooking oil across Karnataka over the last two years, the state Food Safety and Drug Administration (FDA) on Wednesday issued fresh directions to edible oil manufacturers, hotels, and bakeries to strengthen compliance with food safety norms. All cooking oil manufacturing units have now been directed to fortify their products with Vitamins A and D, maintain strict hygiene standards, and get their oils tested every six months. Proper labelling in line with FSSAI norms has also been made mandatory. The move, aimed at improving public health and preventing the unsafe reuse of oil, came during a state-wide video conference chaired by the Food Safety Commissioner. Officials reviewed the functioning of the Repurpose Used Cooking Oil (RUCO) initiative and flagged the need for more responsible handling of used oil.
Mint
an hour ago
- Mint
Booze in energy cans: High Noon recalls vodka seltzer packs after dangerous mix-up
High Noon is recalling certain Beach Variety 12-packs after discovering some contain Celsius Astro Vibe energy drink cans filled with vodka seltzer, instead of non-alcoholic energy drinks. The mix-up happened when a packaging supplier accidentally shipped empty Celsius cans to High Noon's facility, where they were filled with the alcoholic beverage. Though labeled as Celsius Sparkling Blue Razz (with silver lids instead of standard black lids), these cans contain High Noon's 4.5% alcohol vodka seltzer, creating serious risks for children, pregnant women, or those avoiding alcohol for health or religious reasons. The affected products shipped to eight states between July 21-23: Florida, Michigan, New York, Ohio, Oklahoma, South Carolina, Virginia and Wisconsin . Consumers should check 12-pack lot codes printed on box exteriors: L CCC 17JL25 14:00 to 23:59 L CCC 18JL25 00:00 to 03:00 Individual Celsius cans with silver lids and bottom codes L CCB 02JL25 2:55 to 3:11 are also unsafe . No illnesses have been reported, but the FDA warns 'consumption will result in unintentional alcohol ingestion'.
Time of India
9 hours ago
- Time of India
Vinay Prasad education and career: How a summa cum laude MSU graduate rose to lead roles in oncology and at the FDA
Vinay Prasad education and career: How a summa cum laude MSU graduate in philosophy and physiology rose to leading roles in oncology and at the FDA Vinayak "Vinay" Kashyap Prasad, a US physician and health policy researcher, has had a career that spans medicine, academia, and regulatory roles. Known for his work in cancer policy and clinical trial design, Prasad held a prominent leadership position at the US Food and Drug Administration (FDA) before stepping down in July 2025. Prasad served as the Director of the FDA's Center for Biologics Evaluation and Research (CBER) and held the role of Chief Medical and Science Officer during his short tenure at the agency. His appointment and departure from the FDA came amid scrutiny around regulatory decisions involving gene therapy. Academic foundations at Michigan State and beyond Raised in a suburb of Cleveland, Ohio, Prasad later moved to northern Indiana. His academic journey began at Michigan State University (MSU), where he graduated summa cum laude with a double major in philosophy and physiology in 2005. While at MSU, he studied healthcare ethics and gave the commencement address on behalf of the Philosophy Department. Prasad went on to earn his medical degree from the University of Chicago in 2009. He completed a residency in internal medicine at Northwestern University in 2012, receiving the Gerald Grumet Award for best resident teacher. He was board-certified in internal medicine the same year. In 2014, he received a Master of Public Health from Johns Hopkins University. He completed a fellowship in oncology at the National Cancer Institute and in haematology at the National Heart, Lung, and Blood Institute in 2015. During his time at the US National Institutes of Health, he was named Chief Fellow and completed a cancer prevention fellowship. Career in academia and cancer policy research From 2015 to 2020, Prasad served as assistant and then associate professor at Oregon Health & Science University. He later joined the University of California, San Francisco (UCSF), as a professor in the Department of Epidemiology and Biostatistics. There, he led the VKPrasad Lab, focusing on cancer drugs, clinical trials, and health policy. He also worked clinically at San Francisco General Hospital. Prasad is the author of over 500 academic articles and two books: Ending Medical Reversal (2015) and Malignant (2020). His research focuses on drug development, healthcare policy, and the quality of medical evidence. He is also known for examining financial conflicts in drug approvals. FDA appointment and departure in 2025 Prasad was appointed Director of the FDA's CBER on May 6, 2025. The role placed him at the centre of US regulatory oversight for biologics, including vaccines and gene therapies. He was later named the FDA's Chief Medical and Science Officer. According to a spokesperson from the US Department of Health and Human Services, Prasad resigned on July 29, 2025, to return to California and spend more time with his family. The resignation followed internal debate around the FDA's response to safety concerns involving the gene therapy drug Elevidys, manufactured by Sarepta Therapeutics. Teaching and public engagement Prasad has received multiple teaching awards, including the 2017 Craig Okada Award for best teacher in the Haematology-Oncology Fellowship programme and the 2019 J. David Bristow Award, voted by graduating medical students. He is also active in public education through his podcast Plenary Session, his YouTube channel, Substack publications, and The Drug Development Letter. He is based in California and continues his academic and clinical work at UCSF. TOI Education is on WhatsApp now. Follow us here . Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
